To evaluate zinc status in Alzheimer’s disease and Parkinson’s disease, 29 patients with Alzheimer’s disease, 30 patients with Parkinson’s disease, and 29 age- and sex-matched controls were studied. All patients and controls were older than age 50, and all zinc and copper supplements were prohibited beginning 30 days prior to study. Patients were diagnosed by standard criteria. Blood zinc and urine zinc were measured. Urine zinc was measured in a casual specimen, standardized for dilution by reference to creatinine content. Results showed a significantly lower blood zinc in patients with Alzheimer’s and patients with Parkinson’s than in controls. Urine zinc excretion, normalized to urine creatinine excretion, was not significantly different in either patient group compared to controls. These patients are probably zinc deficient because of nutritional inadequacy.
Prasad ASClinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol. 2008;43(5):370-377.
2.
Brewer G., Kanzer SH, Zimmerman E., Heckman S.Sub-clinical zinc deficiency found in Alzheimer’s disease. Alzheimers Dement. 2009;5:e22.
3.
Baum L., Chan IH, Cheung SK, et al. Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability. Biometals.2010;23(1):173-179.
4.
Prasad AS, Meftah S., Abdallah J., et al. Serum thymulin in human zinc deficiency. J Clin Invest. 1988;82(4):1202-1210.
5.
Prasad ASZinc deficiency: its characterization and treatment. Met Ions Biol Syst. 2004;41:103-137.
6.
Perry G., Taddeo MA, Petersen RB, et al. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals. 2003;16(1):77-81.
7.
Newsome DA, Swartz M., Leone NC, Elston RC, Miller E.Oral zinc in macular degeneration. Arch Opthamol. 1988;106(2):192-198.
8.
McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
9.
Morris JCThe Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
10.
Folstein MF , Folstein SE, McHugh PR "Mini-mental state’’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
11.
Sheikh JI, Yesabage JAGeriatric Depression Scale (GDS): Recent Evidence and Development of a Shorter Version. Clinical Gerontology: A Guide to Assassment and Intervention . New York: The Haworth Press; 1986.
12.
Rosen WG, Mohs RC, Davis KLA new rating scale for Alzheimer’s disease. Am J Psychiatry . 1984;141(11):1356-1364.
13.
Duke OARS.Multi-Dimensional Functional Assessment: The OARS Methodology. Durham, NC: Duke University Center for the Study of Aging and Human Development; 1978.
14.
Daniel SE, Lees AJParkinson’s Disease Society Brain Bank, London: overview and research . J Neural Transm Suppl. 1993;39:165-172.
15.
Fahn S., Elton RLUnified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson’s Disease. Florham Park, NJ: Macmillan Health Care Information;1987:153-164.
16.
Hoehn MM, Yahr MDParkinsonism: onset, progression and mortality. Neurology . 1967;17(5):427-442.
17.
Heinegard D. , Tiderstrom G.Determination of serum creatinine by a direct colorimetric method. Clin Chim Acta. 1973;43(3):305-310.
18.
Constantinides J.Treatment of Alzheimer’s disease by zinc compounds. Drug Dev Res. 1992;27:1-14.
19.
Izumi Y., Auberson YP, Zorumski CFZinc modulates bidirectional hippocampal plasticity by effects on NMDA receptors . J Neurosci. 2006;26(27):7181-7188.
20.
Strozyk D., Launer LJ, Adlard PA, et al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging.2009;30(7):1069-1077.
21.
Molina JA, Jimenez-Jimenez FJ, Aguilar MV, et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer’s disease. J Neural Transm. 1998;105(4-5):479-488.
22.
Jeandel C., Nicolas MB, Dubois F., Nabet-Belleville F., Penin F., Cuny G.Lipid peroxidation and free radical scavengers in Alzheimer’s disease . Gerontology. 1989;35(5-6):275-282.
23.
Dong J., Robertson JD, Markesbery WR, Lovell MASerum zinc in the progression of Alzheimer’s disease. J Alzheimer Dis. 2008;15(3):443-450.
Religa D., Strozyk D., Cherny RA, et al. Elevated cortical zinc in Alzheimer disease. Neurology. 2006;67(1):69-75.
26.
Cornett CR, Markesbery WR, Ehmann WDImbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. Neurotoxicology. 1998;19(3):339-345.
27.
Deibel MA, Ehmann WD, Markesbery WRCopper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J Neurol Sci. 1996;143(1-2):137-142.
